ADA and rheumatoid arthritis: Therefore, our findings still needed validation by further randomized‐controlled trials; (3) selection and information bias would exist in this retrospective study; (4) the follow‐up duration could be expanded to compare the long‐term efficacy of ADA and ETN in RA patients; (5) direct efficacy and safety comparisons among different small‐molecule Janus kinase inhibitors, such as tofacitinib, baricitinib, filgotinib, and upadacitinib, in RA patients in real‐world settings deserved to be further investigated.